Table 3.
Prognostic factors for response
| Variable | Level | OR (95% CI) | p-value |
|---|---|---|---|
| Tumour grading | G1 (ref) | - | - |
| G2 | 4.5 (0.5, 38.2) | 0.164 | |
| G3 | 8.4 (0.9, 81.1) | 0.066 | |
| Primary site | Pancreas (ref) | - | - |
| Small bowel | 0.1 (0.0, 0.5) | 0.002 | |
| Baseline MITVSSR | Per 100 ml increase | 1.0 (0.9, 1.2) | 0.478 |
| Baseline VIPSSR | Per 10 SUV x l increase | 1.2 (0.6, 2.6) | 0.592 |
| Baseline GaTate SUVmax | Per 10 units increase | 1.1 (1.0, 1.3) | 0.130 |
| Baseline MITVFDG | Per 10 ml increase | 1.0 (1.0, 1.1) | 0.432 |
| Baseline VIPFDG | Per 100 SUV x ml increase | 1.0 (0.9, 1.1) | 0.569 |
| Baseline FDG SUVmax | Per 5 units increase | 1.2 (0.7, 2.0) | 0.457 |
| Baseline phenotype | GaTate vol greater than FDG (ref) | - | - |
| GaTate vol same as FDG | 1.4 (0.2, 9.4) | 0.705 | |
| GaTate + and FDG- | 0.5 (0.1, 2.3) | 0.411 | |
| Unevaluable | 1.0 (0.3, 3.3) | 0.939 | |
| Cumulative Lu-177 activity | Per 10 GBq increase | 1.3 (0.7, 2.5) | 0.391 |
| Index lesion cumulative radiation dose | Per 50 Gy increase | 1.6 (1.1, 2.2) | 0.006 |
| Index lesion cycle 1 radiation dose | Per 10 Gy increase | 1.3 (1.1, 1.6) | 0.003 |
| Measurable lesion cycle 1 Radiation Dose | Per 10 Gy increase | 1.5 (1.2, 2.0) | 0.001 |
| CLD cumulative radiation dose | Per 50 Gy increase | 1.6 (1.1, 2.5) | 0.023 |
| Radiosensitising chemotherapy | No (ref) | - | - |
| Yes | 1.7 (0.6, 5.4) | 0.330 | |
| Number of radiosensitising chemotherapy cycles | Per unit increase | 1.0 (0.6, 1.9) | 0.901 |